Psychopharmacology Debates: Tylenol or NSAIDs?

When you reach for a pain reliever at the pharmacy, you're likely choosing between two main types of medications: acetaminophen (also known as Tylenol or paracetamol) and nonsteroidal anti-inflammatory drugs, commonly called NSAIDs, which include familiar names like ibuprofen (Advil, Motrin) and naproxen (Aleve).

CLICK TO HEAR THIS POST NARRATED

Conflating acetaminophen with NSAIDs risks selecting a less effective medication and endangers safety in special populations like older adults and pregnant mothers.

Disclaimer

The information provided in this post is for educational purposes only and does not constitute medical advice. The author is not a medical professional. Decisions about medication and treatment should always be made in consultation with your licensed healthcare provider.

Introduction

While these medications are readily available without a prescription, understanding their differences, benefits, and risks is crucial for safe and effective use.

Healthcare professionals frequently guide patients in selecting between these options, and the choice isn't always straightforward. Each medication class works differently in the body, offers distinct benefits, and carries unique risks that must be carefully considered based on individual circumstances. The landscape of medical knowledge about these common drugs continues to evolve, with new research revealing complexities in how they work and new safety considerations emerging from ongoing studies and regulatory reviews.

How These Medications Work

Acetaminophen has been used for over a century, yet scientists are still uncovering exactly how it relieves pain and reduces fever. Unlike NSAIDs, acetaminophen works primarily in the brain and spinal cord rather than throughout the body, which explains why it's effective for pain and fever but doesn't reduce inflammation like NSAIDs do (Li et al., 2013; Mallet et al., 2023; Patel et al., 2024).

The current understanding suggests acetaminophen works through multiple pathways in the central nervous system. While it may affect the same COX enzymes that NSAIDs target, it doesn't bind to them in the same way. Instead, it appears to reduce their activity through a different mechanism, possibly by converting the active form of these enzymes to an inactive state (Li et al., 2013; Ouellet & Percival, 2001; Patel et al., 2024).

Scientists have proposed that acetaminophen might work through a variant of the COX enzyme called COX-3, which is found mainly in the brain. However, this theory hasn't been definitively proven in humans, and recent research suggests this interaction may not be as important as once thought (Graham & Scott, 2005; Graham, Scott, & Day, 2005; Hawkey, 1999; Lee, 2004; Patel et al., 2024; Whelton, 1999).

A significant breakthrough in understanding acetaminophen came with the discovery that the body converts it into an active compound called AM404 in the brain and spinal cord. This metabolite activates specific receptors (TRPV1) that are crucial in how we experience pain. AM404 may also enhance the body's natural pain-relieving systems by affecting cannabinoid pathways and stimulating serotonin-based pain control mechanisms (Mallet et al., 2023; Ouellet & Percival, 2001; Patel et al., 2024). Matuuf and colleagues (2025) reported that primary sensory neurons naturally synthesize AM404. They proposed that the primary analgesic effect of this acetaminophen metabolite is caused by its direct blockade of voltage-gated sodium channels (NaV) 1.8 and 1.7 on peripheral nociceptive neurons.

NSAIDs work quite differently. These medications, including ibuprofen, naproxen, and aspirin, block enzymes called COX-1 and COX-2 throughout the body. These enzymes produce compounds called prostaglandins, which cause inflammation, pain, and fever. By blocking prostaglandin production, NSAIDs effectively reduce all three symptoms (Gaba et al., 2020; Graham, Scott, & Day, 2005; Hawkey, 1999; Lee, 2004; Whelton, 1999).

The two COX enzymes have different roles in the body. COX-1 is always present and helps maintain normal functions like protecting the stomach lining, supporting blood clotting, and maintaining kidney function. COX-2, on the other hand, increases dramatically at sites of injury or inflammation. This distinction is important because while blocking COX-2 provides the anti-inflammatory benefits, blocking COX-1 can lead to side effects like stomach problems (Daniels et al., 2016; Hawkey, 1999).

Traditional NSAIDs like ibuprofen and naproxen block both COX enzymes, which explains both their effectiveness and their side effects. Newer selective COX-2 inhibitors like celecoxib were developed to target only COX-2, aiming to reduce inflammation without affecting COX-1. However, these selective drugs have revealed other safety concerns, particularly regarding heart health (Gunter et al., 2017; Hawkey, 1999).

When to Use Acetaminophen and NSAIDs

Acetaminophen excels at treating mild to moderate pain when inflammation isn't a major factor.

It's particularly effective for tension headaches, general aches and pains, and fever reduction. For osteoarthritis, especially mild to moderate cases, acetaminophen is often recommended as a first choice due to its generally safer profile compared to NSAIDs (Abdulla et al., 2013; Agrawal & Khazaeni, 2024; Li et al., 2013; Patel et al., 2024).

The medication's gentler effect on the stomach makes it preferable for people with a history of stomach problems, ulcers, or those at higher risk for gastrointestinal complications from NSAIDs. While some research questions its effectiveness for common cold symptoms, it remains widely used and recommended for managing fever and discomfort associated with colds (Graham, Scott, & Day, 2005; Hawkey, 1999; Lee, 2004; Li et al., 2013; Whelton, 1999).

NSAIDs shine when inflammation is a significant component of the problem. They're particularly effective for conditions like rheumatoid arthritis, where they help manage pain, stiffness, and swelling. While they don't change the underlying disease process in arthritis, they significantly improve quality of life when used alongside disease-modifying treatments (American College of Rheumatology, n.d.; Fraenkel et al., 2021).

For menstrual cramps, NSAIDs are considered the gold standard treatment. Since menstrual pain is caused by excess prostaglandins in the uterus, NSAIDs' ability to block prostaglandin production makes them particularly effective, often more so than acetaminophen (Mayo Clinic, 2022; Osayande & Mehulic, 2014).

NSAIDs also excel in treating acute injuries like sprains and strains where inflammation contributes to pain and impaired function. Topical NSAID preparations, such as gels containing diclofenac or ibuprofen, can provide localized relief with potentially fewer whole-body side effects (Derry et al., 2015; Gaba et al., 2020).

When choosing between different NSAIDs, considerations include how long they work and how quickly they act. Naproxen lasts longer in the body (12-17 hours) compared to ibuprofen (2-3 hours), allowing for less frequent dosing. This can be particularly helpful for managing persistent pain and may improve adherence to treatment. Naproxen sodium, a salt form, is absorbed more quickly than regular naproxen, making it better for acute pain relief (Brutzkus et al., 2023; Daniels et al., 2016; Strand et al., 2024).

Understanding the Risks

Despite being available without prescription, both medication types carry important risks that vary significantly between individuals and increase with higher doses and longer use.

The most prominent difference in safety profiles relates to stomach and intestinal effects.

NSAIDs can cause a range of gastrointestinal problems, from mild upset to serious complications like bleeding ulcers.

This happens because NSAIDs block the COX-1 enzyme that normally helps protect the stomach lining.

Risk factors for these complications include older age, previous ulcer disease, concurrent use of blood thinners or steroids, high doses, and prolonged use (Abdulla et al., 2013; Daniels et al., 2016; FDA, 2024; Gaba et al., 2020; Graham, Scott, & Day, 2005; Hawkey, 1999; Lee, 2004; Mazur-Bialy & Bilovol, 2015; Whelton, 1999).

Acetaminophen, when used at recommended doses, is much gentler on the stomach and doesn't cause the direct stomach injury associated with NSAIDs. This makes it a better choice for people with stomach sensitivities or ulcer history (Graham et al., 2005; Graham, Scott, & Day, 2005; Hawkey, 1999; Lee, 2004; Li et al., 2013; Whelton, 1999).

Cardiovascular safety has become a major concern with NSAIDs. Both traditional NSAIDs and selective COX-2 inhibitors can increase the risk of heart attacks and strokes. This risk can appear early in treatment and increases with longer use and higher doses. The mechanism involves an imbalance in substances that affect blood vessel function and clotting. Among NSAIDs, naproxen may carry a somewhat lower cardiovascular risk, while diclofenac and COX-2 inhibitors often show higher risk.

People with existing heart disease or multiple cardiovascular risk factors face the greatest danger (Daniels et al., 2016; FDA, 2024; Gunter et al., 2017). Acetaminophen doesn't carry these cardiovascular thrombotic risks, making it often a safer choice for people with heart disease concerns (Graham, Scott, & Day, 2005; Hawkey, 1999; Lee, 2004; Whelton, 1999).

Both medications can affect kidney function, though through different mechanisms. NSAIDs interfere with prostaglandins that help maintain kidney blood flow, particularly important when kidney function is already stressed. This can lead to acute kidney injury, fluid retention, elevated potassium levels, and high blood pressure. Risk is highest in older adults, people with existing kidney disease, diabetes, or heart failure, and those taking certain blood pressure medications (Graham, Scott, & Day, 2005; Hawkey, 1999; Lee, 2004; Tubbs et al., 2023; Whelton, 1999).

While acetaminophen has traditionally been considered safer for the kidneys, emerging research suggests chronic or high-dose use may also increase kidney disease risk. Some studies have found a 23% higher risk of kidney problems in regular acetaminophen users, though other research disputes this connection. Regular use has also been linked to increased blood pressure in some studies.

While acetaminophen likely remains safer than NSAIDs for most people with kidney concerns, its safety shouldn't be assumed absolute (Hiragi et al., 2018; Jo et al., 2020; Tubbs et al., 2023).

The liver presents acetaminophen's most serious risk.

Overdose is a leading cause of acute liver failure in many countries. At normal doses, the liver safely processes acetaminophen, but in overdose, toxic metabolites accumulate and cause liver damage. Risk factors include exceeding recommended doses (often unintentionally due to acetaminophen being in many combination products), chronic heavy alcohol use, poor nutrition, and existing liver disease. The widespread presence of acetaminophen in numerous products makes unintentional overdose a significant public health concern (Abdulla et al., 2013; Agrawal & Khazaeni, 2024; GetReliefResponsibly.com, 2017; Graham et al., 2005; Lee, 2004; Patel et al., 2024).

While less common, NSAIDs can also cause liver problems, typically as unpredictable reactions ranging from mild enzyme elevations to severe hepatitis. Diclofenac and sulindac are more frequently implicated in liver injury (Gaba et al., 2020; Mourad et al., 2004).

Special Considerations for Pregnancy

Medication use during pregnancy requires exceptional caution.

Acetaminophen has generally been considered the safer option during pregnancy when used appropriately, though it should still be used only when necessary, at the lowest effective dose, and for the shortest duration (Graham, Scott, & Day, 2005; Hawkey, 1999; Lee, 2004; Whelton, 1999).

The FDA significantly updated NSAID pregnancy warnings in October 2020, representing a major shift in practice. Pregnant women should now avoid NSAIDs from 20 weeks of pregnancy onward unless specifically directed by a healthcare provider. This earlier cutoff reflects newly recognized risks of rare but serious kidney problems in the developing baby. Around 20 weeks, fetal kidneys begin producing most of the amniotic fluid. NSAIDs can impair this function, leading to dangerously low amniotic fluid levels that can cause impaired lung development, limb problems, and umbilical cord compression (FDA, 2020).

If NSAID use is essential between 20 and 30 weeks, it should be limited to the lowest dose for the shortest time, with consideration for ultrasound monitoring if treatment extends beyond 48 hours. The longstanding concern about NSAIDs in the third trimester remains, as they can cause premature closure of a fetal blood vessel, potentially leading to serious complications in the newborn. An important exception is low-dose aspirin under medical supervision for preventing certain pregnancy complications (American College of Rheumatology, n.d.; FDA, 2020; Graham, Scott, & Day, 2005; Hawkey, 1999; Lee, 2004; Whelton, 1999). Table 1: FDA Recommendations for NSAID Use in Pregnancy (From 20 Weeks Gestation)

Considerations for Older Adults

People aged 65 and older face increased risks from both medications due to age-related changes in how the body processes drugs, higher rates of other health conditions, and frequent use of multiple medications. While acetaminophen is often recommended as first-line treatment for chronic pain conditions like osteoarthritis in older adults, its use requires careful consideration. Frail elders, those with poor nutrition, or those who drink alcohol regularly may face increased liver toxicity risk. Lower maximum daily doses may be appropriate for these individuals (Abdulla et al., 2013; Graham, Scott, & Day, 2005; Hawkey, 1999; Lee, 2004; Whelton, 1999).

NSAIDs pose significantly higher risks in older adults, including substantially increased chances of stomach bleeding, kidney problems, and cardiovascular events.

The principle of "start low, go slow" is crucial, but thorough individual risk assessment considering all health conditions and medications is essential rather than simply defaulting to one medication over another (Abdulla et al., 2013; FDA, 2024; Tubbs et al., 2023).

Proper Dosing and Combination Use

Following appropriate dosing guidelines is critical for safety. The general principle, especially for NSAIDs, is using the lowest effective dose for the shortest duration needed. Patients must carefully read labels to identify active ingredients in all medications to avoid unintentional overdose, particularly with acetaminophen-containing combination products (FDA, 2024; GetReliefResponsibly.com, 2017). Table 2: Recommended Over-the-Counter (OTC) Dosing for Adults and Children ≥12 Years

Combining acetaminophen with a single NSAID can provide enhanced pain relief by targeting different pain pathways. Studies show this combination can improve pain control, particularly after surgery, without significantly increasing side effects when each drug stays within recommended limits.

However, using multiple different NSAIDs together should always be avoided as it significantly increases risks without providing additional benefits (Hyllested et al., 2002; Mazur-Bialy & Bilovol, 2015; Merry et al., 2019; Mourad et al., 2004).

Making Informed Choices

Selecting between acetaminophen and NSAIDs requires understanding their distinct properties, effectiveness profiles, and potential risks in the context of individual health circumstances.

Acetaminophen generally works best for mild to moderate pain without significant inflammation and for fever reduction.

Its central mechanism of action provides pain relief with lower risks of stomach and cardiovascular problems compared to NSAIDs, though liver toxicity remains a serious concern with overdose or in susceptible individuals.

NSAIDs excel when inflammation drives symptoms, making them superior choices for conditions like arthritis, injuries with swelling, and menstrual cramps.

However, their mechanism of blocking prostaglandins throughout the body creates risks for the stomach, heart, and kidneys that must be carefully weighed against benefits.

The key to safe and effective use lies in individualized assessment considering the type and severity of pain, presence of inflammation, existing health conditions, age, pregnancy status, and other medications. What works best for one person may not be appropriate for another. Understanding these nuances empowers patients and healthcare providers to make informed decisions that maximize benefits while minimizing risks, ensuring these common medications are used as safely and effectively as possible.

Table 3: Comparative Overview of Acetaminophen and NSAIDs

Key Takeaways

1. Choose acetaminophen for non-inflammatory pain (headaches, mild arthritis, fever) and if you have stomach problems or heart disease risks. Choose NSAIDs when inflammation is present (sprains, menstrual cramps, inflammatory arthritis).

   
   

2. Never exceed daily dose limits: Acetaminophen maximum is 3,000-4,000 mg daily, but check all your medications as it's hidden in many products. NSAIDs like ibuprofen max out at 1,200 mg daily for OTC use.

   
   

3. Avoid NSAIDs if you're pregnant past 20 weeks, have kidney disease, heart disease, or stomach ulcers. Acetaminophen is generally safer but watch for liver risks, especially with alcohol use or malnutrition.

   
   

4. Combining acetaminophen with one NSAID is safe and often more effective than either alone, but never take multiple NSAIDs together (including aspirin) as this multiplies risks without adding benefits.

   
   

5. Use the lowest effective dose for the shortest time needed, especially for NSAIDs and in older adults who face higher risks from both medications. When in doubt, consult a healthcare provider rather than self-treating long-term.

Glossary

AM404 (N-arachidonoylphenolamine): an active metabolite of acetaminophen formed in the brain, believed to contribute significantly to its analgesic effects through activation of TRPV1 receptors and modulation of the endocannabinoid system.

analgesic: a medication designed to relieve pain without causing loss of consciousness.

antipyretic: a substance capable of reducing fever.

COX-1 (Cyclooxygenase-1): a constitutively expressed enzyme involved in physiological "housekeeping" functions, such as gastric mucosal protection, platelet aggregation, and renal homeostasis.

COX-2 (Cyclooxygenase-2): an enzyme that is primarily inducible at sites of inflammation and injury, playing a key role in the synthesis of prostaglandins that mediate pain and inflammation. It also has constitutive roles in some tissues.

COX-3: a hypothesized splice variant of COX-1, predominantly found in the canine brain, once suggested as a primary target for acetaminophen. Its relevance in humans is uncertain.

cyclooxygenase (COX): a family of enzymes (including COX-1 and COX-2) responsible for the synthesis of prostaglandins from arachidonic acid.

dysmenorrhea: painful menstruation, often characterized by uterine cramps.

hepatotoxicity: chemical-driven liver damage or injury.

multimodal analgesia: the use of multiple analgesic drugs or techniques that act by different mechanisms, with the goal of achieving additive or synergistic pain relief and reducing the doses and side effects of individual components.

N-acetyl-p-benzoquinone imine (NAPQI): a highly reactive and toxic metabolite of acetaminophen, produced via cytochrome P450 metabolism. It is responsible for acetaminophen-induced hepatotoxicity when glutathione stores are depleted.

nephrotoxicity: kidney damage or dysfunction resulting from exposure to toxic substances, including certain medications.

NSAIDs (Nonsteroidal Anti-inflammatory Drugs): a class of drugs that reduce pain, fever, and inflammation by inhibiting cyclooxygenase (COX) enzymes and thus prostaglandin synthesis. Examples include ibuprofen, naproxen, and aspirin.

oligohydramnios: a condition characterized by a deficiency of amniotic fluid surrounding the fetus during pregnancy.

pharmacodynamics: the study of the biochemical and physiological effects of drugs on the body and their mechanisms of action.

pharmacokinetics: the study of the absorption, distribution, metabolism, and excretion (ADME) of drugs by the body.

prostacyclin (PGI2): a prostaglandin produced primarily by endothelial cells, which has vasodilatory effects and inhibits platelet aggregation.

prostaglandins: a group of lipid compounds derived from fatty acids (like arachidonic acid) that have diverse hormone-like effects in the body, including significant roles in inflammation, pain, fever, blood clotting, and protection of the gastric lining.

thromboxane A2 (TXA2): a substance produced primarily by platelets (via COX-1) that causes vasoconstriction and promotes platelet aggregation.

TRPV1 (Transient Receptor Potential Vanilloid 1): an ion channel found on sensory neurons that is involved in the detection and transduction of noxious stimuli, including heat and capsaicin. It is a target for the acetaminophen metabolite AM404.

References

Abdulla, A., Adams, N., Bone, M., Elliott, A. M., Gaffin, J., Jones, D., Knaggs, R., Martin, D., Sampson, L., & Schofield, P. (2013). Guidance on the management of pain in older people. Age and Ageing, 42(Suppl 1), i1-i57. https://doi.org/10.1093/ageing/afs200

Agrawal, S., & Khazaeni, B. (2024). Acetaminophen toxicity. In StatPearls. StatPearls Publishing. American College of Rheumatology. (n.d.). NSAIDs (nonsteroidal anti-inflammatory drugs). https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Treatments/NSAIDs

Brutzkus, J. C., Shahrokhi, M., & Varacallo, M. (2023). Naproxen. In StatPearls. StatPearls Publishing.

Daniels, S. E., Bandy, D. P., Christensen, S. E., Boice, J., & Losada, M. C. (2016). Evaluation of the dose range of etoricoxib in an acute pain setting using the postoperative dental pain model. The Clinical Journal of Pain, 32(6), 443-450. https://doi.org/10.1097/AJP.0000000000000290

Derry, S., Moore, R. A., Gaskell, H., McIntyre, M., & Wiffen, P. J. (2015). Topical NSAIDs for acute musculoskeletal pain in adults. Cochrane Database of Systematic Reviews, (6), CD007402. https://doi.org/10.1002/14651858.CD007402.pub3

FDA. (2020). FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic

FDA. (2024). Nonsteroidal anti-inflammatory drugs (NSAIDs). U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-safety-and-availability/nonsteroidal-anti-inflammatory-drugs-nsaids

Fraenkel, L., Bathon, J. M., England, B. R., St Clair, E. W., Arayssi, T., Carandang, K., Deane, K. D., Genovese, M., Huston, K. K., Kerr, G., Kremer, J., Nakamura, M. C., Russell, L. A., Singh, J. A., Smith, B. J., Sparks, J. A., Venkatachalam, S., Weinblatt, M. E., Al-Gibbawi, M., ... Akl, E. A. (2021). 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care & Research, 73(7), 924-939. https://doi.org/10.1002/acr.24596

Gaba, A., Mairhofer, C., Zhegu, Z., Leditznig, N., Szabo, S., Tscholakoff, B., Zinnanti, J., Lebeda, M., Petre, B. A., & Kaniusas, E. (2020). Comparison of local and systemic pharmacokinetics of diclofenac from various topical formulations. Heliyon, 6(12), e05677. https://doi.org/10.1016/j.heliyon.2020.e05677

GetReliefResponsibly.com. (2017). Use medicines safely. https://www.getreliefresponsibly.com/use-medicines-safely/

Graham, G. G., & Scott, K. F. (2005). Mechanism of action of paracetamol. American Journal of Therapeutics, 12(1), 46-55. https://doi.org/10.1097/00045391-200501000-00008

Graham, G. G., Scott, K. F., & Day, R. O. (2005). Tolerability of paracetamol. Drug Safety, 28(3), 227-240. https://doi.org/10.2165/00002018-200528030-00004

Gunter, B. R., Butler, K. A., Wallace, R. L., Smith, S. M., & Harirforoosh, S. (2017). Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: A meta-analysis. Journal of Clinical Pharmacy and Therapeutics, 42(1), 27-38. https://doi.org/10.1111/jcpt.12484

Hawkey, C. J. (1999). COX-2 inhibitors. The Lancet, 353(9149), 307-314. https://doi.org/10.1016/S0140-6736(98)12154-2

Hiragi, S., Yamada, H., Tsukamoto, T., Yoshida, K., Kondo, N., Matsubara, T., Yanagita, M., Tamura, H., & Kuroda, T. (2018). Acetaminophen administration and the risk of acute kidney injury: A self-controlled case series study. Clinical Epidemiology, 10, 265-276. https://doi.org/10.2147/CLEP.S158110

Hyllested, M., Jones, S., Pedersen, J. L., & Kehlet, H. (2002). Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: A qualitative review. British Journal of Anaesthesia, 88(2), 199-214. https://doi.org/10.1093/bja/88.2.199

Jo, H., Kim, S. A., Kim, K., Chang, J., Suh, H. S., Kronbichler, A., Lee, K. H., & Shin, J. I. (2020). Association between regular acetaminophen use and renal impairment in patients with or without chronic kidney disease: A systematic review and meta-analysis. Scientific Reports, 10(1), 17653. https://doi.org/10.1038/s41598-020-74466-2

Lee, W. M. (2004). Acetaminophen and the U.S. Acute Liver Failure Study Group: Lowering the risks of hepatic failure. Hepatology, 40(1), 6-9. https://doi.org/10.1002/hep.20293

Li, S., Yue, J., Dong, B. R., Yang, M., Lin, X., & Wu, T. (2013). Acetaminophen (paracetamol) for the common cold in adults. Cochrane Database of Systematic Reviews, (7), CD008800. https://doi.org/10.1002/14651858.CD008800.pub2

Maatuf, Y., Kushnir, Y., Nemirovski, A., Ghantous, M., Iskimov, A., Binshtok, A. M., & Priel, A. (2025). The analgesic paracetamol metabolite AM404 acts peripherally to directly inhibit sodium channels. Proceedings of the National Academy of Sciences of the United States of America, 122(23), e2413811122. https://doi.org/10.1073/pnas.2413811122

Mallet, C., Desmeules, J., Pegahi, R., & Eschalier, A. (2023). An updated review on the metabolite (AM404)-mediated central mechanism of action of paracetamol (acetaminophen): Experimental evidence and potential clinical impact. Journal of Pain Research, 16, 1081-1094. https://doi.org/10.2147/JPR.S393809

Mayo Clinic. (2022). Menstrual cramps. https://www.mayoclinic.org/diseases-conditions/menstrual-cramps/symptoms-causes/syc-20374938

Mazur-Bialy, A. I., & Bilovol, O. M. (2015). Gastrointestinal complications of non-steroidal anti-inflammatory drugs and prevention strategies: A review. Polski Merkuriusz Lekarski, 39(232), 231-235.

Merry, A. F., Gibbs, R. D., Edwards, J., Ting, G. S., Frampton, C., Davies, E., & Anderson, B. J. (2019). Combined acetaminophen and ibuprofen for pain relief after oral surgery in adults: A randomized controlled trial. British Journal of Anaesthesia, 104(1), 80-88. https://doi.org/10.1093/bja/aep338

Mourad, A. A., Bahna, S. G., & Haidar, J. H. (2004). Hepatotoxicity with the use of nonsteroidal anti-inflammatory drugs. Le Journal Médical Libanais, 52(3), 123-127.

Osayande, A. S., & Mehulic, S. (2014). Diagnosis and initial management of dysmenorrhea. American Family Physician, 89(5), 341-346.

Ouellet, M., & Percival, M. D. (2001). Mechanism of acetaminophen inhibition of cyclooxygenase isoforms. Archives of Biochemistry and Biophysics, 387(2), 273-280. https://doi.org/10.1006/abbi.2000.2232

Patel, R., Soni, M., Soyantar, B., Shivangi, S., Sutariya, S., Saraf, M., & Goswami, S. (2024). A clash of titans: Acetaminophen/paracetamol wars. International Journal of Pharmaceutics, 649, 123627. https://doi.org/10.1016/j.ijpharm.2023.123627

Strand, V., Johnson, P., & Baraf, H. S. B. (2024). Oral non-steroidal anti-inflammatory drugs in treatment of pain due to musculoskeletal disorders: A review of the evidence. Journal of Pain Research, 17, 1247-1270. https://doi.org/10.2147/JPR.S462205

Tubbs, A., Willoughby, H., Alruwaili, A., Hua, Y., Lombardo, M., Dehlin, J., Vanatta, P., Cusick, A., Brown, K., & Harrell, M. B. (2023). Acetaminophen toxicity in patients with chronic kidney disease: A review of the current evidence. Nephrology Dialysis Transplantation, 38(Supplement_1), i3223-i3229. https://doi.org/10.1093/ndt/gfad063c_5612

Whelton, A. (1999). Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. The American Journal of Medicine, 106(5B), 13S-24S. https://doi.org/10.1016/S0002-9343(99)00113-8

We have extensively revised our Brodmann Areas resource with new research and graphics.

Support Our Friends

Choosing Between Acetaminophen and NSAIDs.pdf

Download PDF • 775KB